In an adult with cirrhosis, ascites and rapidly rising serum creatinine (hepatorenal syndrome), what is the recommended terlipressin and albumin regimen, including dosing, duration, and monitoring?

Terlipressin and Albumin Regimen for Hepatorenal Syndrome

For adults with cirrhosis, ascites, and rapidly rising serum creatinine consistent with hepatorenal syndrome-AKI (HRS-AKI), initiate terlipressin 1 mg IV every 4-6 hours (total 4-6 mg/day) plus albumin 1 g/kg IV on day 1 (maximum 100 g) followed by 20-40 g daily, continuing until serum creatinine returns to within 0.3 mg/dL of baseline for 2 consecutive days or for a maximum of 14 days. 1

Initial Assessment and Prerequisites

Before starting terlipressin, you must:

• Confirm HRS-AKI diagnosis: Serum creatinine ≥2× baseline (Stage 2 or greater AKI) that persists after 48 hours of diuretic withdrawal and volume expansion with albumin 1 g/kg for 2 days 1
• Rule out contraindications: Serum creatinine ≥5 mg/dL, oxygen saturation <90%, shock, sepsis, or uncontrolled infection 1, 2
• Screen for cardiovascular disease: Obtain ECG to assess for ischemic heart disease, as terlipressin causes vasoconstriction 3, 1
• Search rigorously for infection: Perform diagnostic paracentesis, blood/urine cultures, and chest X-ray 1

Dosing Protocol

Terlipressin Dosing

Starting dose: 1 mg IV bolus every 4-6 hours (total 4-6 mg/day) 1

Dose escalation on Day 3-4: If serum creatinine has NOT decreased by ≥25% from baseline, increase to 2 mg every 4-6 hours (total 8-12 mg/day) 1

Alternative continuous infusion: Start at 2 mg/24 hours IV continuous infusion, increasing every 24-48 hours up to maximum 12 mg/day. This approach may reduce ischemic side effects compared to bolus dosing 1, 3, 4. The 2024 AASLD guidance specifically recommends 0.5-2.0 mg IV every 6 hours or continuous infusion of 2 mg/24 hours 5.

Administration: Can be given through peripheral IV line; does NOT require ICU monitoring or central line 6, 2

Albumin Dosing

• Day 1: 1 g/kg IV (maximum 100 g) 1, 2
• Days 2-14: 20-40 g daily (or up to 50 g/day based on clinical need) 1, 7, 2

The optimal duration of albumin beyond initial volume expansion remains unclear 1. The 2024 AGA guidance notes albumin's role is primarily volume expansion in the first 1-2 days, with continuation based on careful volume status assessment 6.

Duration of Treatment

Continue therapy until:

• Success: Serum creatinine returns to within ≤0.3 mg/dL of baseline for 2 consecutive days (measured at least 2 hours apart) 1, OR
• Maximum duration: 14 days of therapy 1
• Failure: Serum creatinine remains at or above baseline on Day 4 despite dose escalation 2

The median treatment duration in the pivotal CONFIRM trial was 5 days 2.

Monitoring Requirements

Daily Monitoring

• Serum creatinine: Daily to assess response 1
• Urine output: Target >50 mL/hour for at least 4 hours 1
• Vital signs: Monitor for hypotension or hypertension 1
• Volume status: Use clinical assessment, and when indicated, echocardiography or CVP monitoring to avoid pulmonary edema from excessive albumin 1, 6

Critical Day 3-4 Assessment

This is the decision point for dose escalation or discontinuation:

• If creatinine decreased <25%: Increase terlipressin dose 1
• If creatinine decreased ≥30%: Continue current dose 2
• If creatinine at or above baseline: Consider discontinuing therapy 2

Ischemic Side Effects and Management

Common ischemic complications include angina, finger/skin ischemia, and intestinal ischemia 1. These occurred more frequently in the CONFIRM trial with terlipressin versus placebo 2.

Risk mitigation strategies:

• Start at lowest effective dose and titrate gradually 1
• Consider continuous infusion rather than bolus dosing (may reduce ischemic events) 1, 3, 4
• Perform baseline ECG screening 3
• Monitor closely for chest pain, abdominal pain, or peripheral ischemia
• Reduce dose or discontinue if severe ischemic events occur 3

Alternative Vasoconstrictor Options

If terlipressin is unavailable or contraindicated:

Norepinephrine: 0.5 mg/hour continuous IV infusion, increase by 0.5 mg/hour every 4 hours to maximum 3 mg/hour. Goal: increase MAP by ≥10 mm Hg and/or urine output >50 mL/hour for ≥4 hours. Requires ICU admission and central line 1, 8, 1. The 2024 AASLD guidance notes norepinephrine may be preferred in patients with shock 5.

Midodrine + Octreotide: Start midodrine 7.5 mg PO three times daily, titrate to 12.5 mg three times daily; octreotide 100 mcg SC three times daily, titrate to 200 mcg three times daily 1. However, this combination has much lower efficacy than terlipressin 3, 7 and should only be used when terlipressin and norepinephrine are unavailable 1.

Evidence Quality and Nuances

The 2022 AGA guidelines 1 represent the most current and comprehensive guidance, superseding the older 2009 Hepatology recommendations 8. The pivotal CONFIRM trial 2 demonstrated terlipressin plus albumin achieved 29.1% HRS reversal versus 15.8% with placebo (p=0.012), though without mortality benefit. The FDA approved terlipressin in 2022 based on this trial.

Critical caveat: The 2024 AASLD guidance 5 specifically recommends terlipressin NOT be used in patients with ACLF-3 (EASL-CLIF criteria), as these patients have very high mortality regardless of HRS reversal. This represents an important restriction beyond the FDA label.

Recurrence management: If HRS-AKI recurs after treatment cessation, repeat the full course of therapy 3, 7.

Renal Replacement Therapy Considerations

RRT should be considered for:

• Non-responders to vasoconstrictors who are liver transplant candidates 1, 5, 7
• Standard RRT indications (severe electrolyte/acid-base disturbances, refractory volume overload, symptomatic azotemia) 3

Do NOT initiate RRT in HRS-AKI patients who are not transplant candidates, as mortality remains extremely high 1, 7.

Continuous RRT is preferred over intermittent hemodialysis in hemodynamically unstable patients 5, 3.

Liver Transplantation Context

Liver transplantation is the definitive treatment for HRS-AKI 1. Importantly, patients who respond to terlipressin have better post-transplant outcomes, including lower rates of post-transplant chronic kidney disease and reduced need for RRT 6, 7, 9. This supports treating HRS-AKI with terlipressin even in transplant-listed patients, despite the temporary reduction in MELD score that occurs with treatment response.